The need for a holistic view on management of Clostridioides difficile infection

Sebastian M Wingen-Heimann; Joffrey van Prehn; Eduard J Kuijper; Maria J G T Vehreschild

doi:10.1016/j.cmi.2021.07.014

The need for a holistic view on management of Clostridioides difficile infection

Clin Microbiol Infect. 2021 Oct;27(10):1383-1385. doi: 10.1016/j.cmi.2021.07.014. Epub 2021 Jul 24.

Authors

Sebastian M Wingen-Heimann¹, Joffrey van Prehn², Eduard J Kuijper³, Maria J G T Vehreschild⁴

Affiliations

¹ University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany; FOM University of Applied Sciences, Cologne, Germany. Electronic address: Sebastian.wingen-heimann@uk-koeln.de.
² Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands.
³ Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands; Centre for Infectious Disease, National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
⁴ Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.

PMID: 34311078
DOI: 10.1016/j.cmi.2021.07.014

No abstract available

Keywords: Bezlotoxumab; Clostridioides difficile infection; Cost-effectiveness; Fidaxomicin; Prevention of recurrent Clostridioides difficile infection.

Publication types

Comment

MeSH terms

Clostridium Infections* / diagnosis
Clostridium Infections* / drug therapy
Fidaxomicin
Humans

Substances

Fidaxomicin